AETERNA ZENTARIS INC/ CA0079756007 /
5/23/2024 9:57:59 PM | Chg. - | Volume | Bid10:00:40 PM | Ask10:00:40 PM | High | Low |
---|---|---|---|---|---|---|
11.69CAD | - | 314 Turnover: 3,488 |
11.45Bid Size: 100 | 12.00Ask Size: 100 | 11.69 | 11.59 |
GlobeNewswire
3/27
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...
GlobeNewswire
3/12
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
GlobeNewswire
3/12
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
GlobeNewswire
2/26
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders V...
GlobeNewswire
2/26
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders V...
GlobeNewswire
2/23
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceu...
GlobeNewswire
2/15
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Sec...
GlobeNewswire
2/15
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meetin...
GlobeNewswire
12/14/2023
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Comp...
GlobeNewswire
10/11/2023
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
GlobeNewswire
9/5/2023
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
3/29/2022
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business O...
GlobeNewswire
3/21/2022
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childh...
GlobeNewswire
3/10/2022
Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzbur...